Eosinophils are short-lived effector and regulatory cells that are increasingly recognized as having key roles in the immune system, including maintenance of long-term antibody responses and defence against bacteria and viruses.
1,2 On the other hand, their potentially destructive nature becomes apparent in a number of eosinophilic diseases such as hypereosinophilic syndromes (HES), diseases characterized by eosinophil-mediated tissue damage and organ dysfunction. 3, 4 Eosinophils contribute to disease pathology directly and indirectly by releasing cytotoxic molecules and by supporting an ongoing inflammation.
1 Besides HES, eosinophilia can be observed in a wide range of infectious, allergic and autoimmune diseases, as well as in cancer. 3, 5 Given the increasing incidence of such diseases and the often unsatisfactory treatment options available, it is of considerable importance to better understand factors governing eosinophil biology under both normal and inflammatory conditions. Eosinophil numbers are largely regulated by their production in the bone marrow where they differentiate from myeloid precursors. 6 Lineage commitment is controlled by GATA-1, GATA-2, PU.1 and c/EBP transcription factors. For instance, mice lacking GATA-1 or c/EBP expression are devoid of eosinophils, and transduction of hematopoietic progenitor cells (HPC) with either of these genes promotes differentiation into eosinophils. 7 However, the situation is not always straightforward. Lineage specification and maturation strongly depend on the relative levels of these transcription factors and their interaction partners or competitors. For example, while GATA-2 expression is required for the proper differentiation of several haematopoietic lineages, including eosinophils, 8 high GATA-2 expression inhibits HPC proliferation. 9, 10 Similarly, overexpression of GATA-2 in progenitor cells in the presence of C/EBPα drives eosinophil differentiation, while it promotes mast cell/basophil generation in the absence of C/EBPα. 11 Furthermore, while GATA-2 induces the expression of eosinophil-derived neurotoxin, it also antagonizes GATA-1-mediated expression of other eosinophil-related genes, including major basic protein. [12] [13] [14] These apparently discordant findings highlight the need for a better understanding of the molecular mechanisms controlling eosinophil differentiation.
The best studied cytokines promoting eosinophil development are interleukin (IL)-3, IL-5, and granulocyte/macrophage colony-stimulating factor (GM-CSF). 6 In addition to their role in eosinophilopoiesis, they also enhance eosinophil survival. 15 Of these eosinophil hematopoietins, IL-5 is the most specific for the eosinophil lineage. Transgenic overexpression of IL-5 in mice results in eosinophilia, whereas deletion of the IL-5 gene strongly reduces eosinophil counts in blood and lungs following allergen challenge. 6, 16 Furthermore, many eosinophilic diseases are associated with increased IL-5 levels. 3, 17 These findings together with the knowledge of the critical role of IL-5 for eosinophil generation and survival have prompted the development of therapeutic anti-IL-5 and anti-IL-5 receptor antibodies, which are currently being investigated in eosinophilic disorders. 1, 18 RhoH belongs to the family of small GTPases that are involved in diverse cellular processes, including signalling, vesicle transport, migration, proliferation and differentiation. In contrast to most family members, RhoH is GTPase deficient and, therefore, its activity is assumed to be regulated at the level of protein expression rather than by switching between active (GTP-bound) and inactive (GDP-bound) forms. 19 RhoH is exclusively expressed in the hematopoietic system and is mutated in a number of lymphomas and leukemias, but the mechanisms by which dysregulated RhoH contributes to malignancy remain unclear.
With respect to its physiological functions, RhoH is involved in T-cell receptor (TCR) signalling, where it regulates the subcellular localization of ZAP70 and LCK. [20] [21] [22] Following TCR stimulation, RhoH is degraded. 23 RhoH −/− mice have reduced T-cell numbers due to a failure of positive selection, and impaired peripheral T-cell responses. 21, 24 This phenotype is similar to that of two recently described natural RhoHdeficient siblings, in which impaired T-cell function resulted in susceptibility to certain viral infections. 25 In mast cells, RhoH is critical for FcεRI-dependent signal transduction. 26 RhoH has also been found to negatively regulate several processes, including T-cell adhesion and migration, stem cell proliferation and homing, 27 IL-3 signalling in a B cell line 28 and leukotriene production in neutrophils, 29 but its function in eosinophils is unknown.
In this study, we report that RhoH deficiency promotes, and RhoH overexpression reduces, eosinophil differentiation in vitro and in vivo. Moreover, RhoH induces the developmentally important transcription factor GATA-2 through a Rho-associated protein kinase (ROCK)-dependent mechanism. In addition, RhoH appears to promote cellular quiescence in a manner similar to what has been reported for GATA-2. 10 Furthermore, our data suggest that IL-5 induces RhoH in immature eosinophils, a pathway that also remains functional following maturation. Taken together, our data suggest that IL-5 not only drives eosinophil differentiation, but also induces an inhibitory pathway limiting this process in which RhoH has a major role.
Results
RhoH is expressed in human eosinophils and upregulated upon IL-5 stimulation. To investigate whether RhoH is expressed in eosinophils under physiological conditions, we isolated eosinophils from peripheral blood of healthy donors and found that eosinophils expressed higher levels of RhoH mRNA than peripheral blood mononuclear cells (PBMC) or neutrophils from the same individuals (Figure 1a) . To examine RhoH protein expression in more detail, we isolated different leukocyte subsets for immunoblot analysis. We observed that eosinophils and NK cells express RhoH. In addition, in agreement with the previous observations, 23 RhoH protein was present in T and B cells, but was hardly detectable in monocytes and neutrophils ( Figure 1b) . We next investigated the regulation of RhoH by eosinophil hematopoietins. RhoH was rapidly upregulated in eosinophils in response to IL-5 (Figure 1c ), IL-3 and GM-CSF (Figure 1d ). Of note, the magnitude of the response differed considerably between donors 3 h after stimulation (Figures 1c and d) , ranging from 1.5-fold to more than 10-fold induction, probably reflecting differences in intrinsic responsiveness and/or degrees of pre-activation. The reduction of RhoH signal at later time points is mirrored by a reduction in GAPDH signal and is likely the result of a loss of cell viability.
To address the in vivo relevance of these findings, we assessed RhoH expression in eosinophils from healthy donors and patients with HES, a condition frequently characterized by overproduction of IL-5 or IL-3 by T cells or other cells. 3, 17 We found that in eosinophils from some HES patients, RhoH was upregulated (Figure 1e) . Notably, increased RhoH expression was accompanied by phosphorylation of signal transducer and activator of transcription 3 (STAT3). Why STAT3 phosphorylation varied considerably among HES patients is unclear, as the eosinophilia in all cases was likely driven by at least one of the eosinophil hematopoietins IL-3, IL-5 or GM-CSF and none of these patients had evidence for the presence of an eosinophilic leukemia. Therefore, we speculate that STAT3 phosphorylation is a dynamic process and depends not only on extracellular cytokine concentrations at a given time point. Nevertheless, the increased STAT3 phosphorylation levels point to the possibility that increased RhoH levels in HES patients might have been caused by in vivo exposure to at least one eosinophil hematopoietin. This notion was further substantiated by the finding that eosinophils derived from HES patients failed to further upregulate RhoH in response to in vitro stimulation with IL-5 ( Figure 1f ).
Mature eosinophils from RhoH knockout mice exhibit no abnormalities regarding life span, surface phenotype or migration. To determine the functional role of RhoH in resting and activated eosinophils, we attempted to overexpress RhoH in primary human eosinophils. However, primary granulocytes are notoriously difficult to transfect. As we have previously observed that the use of lentiviruses is not suitable for overexpressing proteins in granulocytes, 30 we tested the nucleofection approach reported by Xu et al. 31 for mouse neutrophils. Using a GFP control construct, we observed GFP expression in up to 40% of eosinophils (Supplementary Figure S1a) . However, we found that the vast majority of eosinophils died during the procedure and surviving eosinophils showed strong signs of nonspecific activation, such as downregulation of the IL-5/IL-3/GM-CSF common β-chain ((CD131); Supplementary Figure S1b ). This is in agreement with a recent publication using human neutrophils and an identical protocol. 32 To circumvent the difficulties experienced with manipulating RhoH levels in human eosinophils, we crossed RhoH −/− mice to mice carrying the IL-5 transgene. IL-5 tg mice have increased levels of eosinophils, allowing their isolation in larger numbers. 16 Eosinophils from RhoH −/− IL-5 tg mice did not show any obvious alterations in cellular viability, migratory behaviour (spontaneous or eotaxin-mediated), surface immunophenotype (IL-5Rα, CCR3, CD62L, Gr-1, CD11b, CD131) or spontaneous and induced cytokine (IL-4, IL-6, IL-13) production compared with eosinophils from IL-5 tg mice ( Figure 2 and data not shown).
RhoH induces GATA-2 expression. As genetic modification of human eosinophils was problematic and functional screening with mouse eosinophils did not uncover a role for RhoH in mature eosinophils, we lentivirally transduced the eosinophilic HL-60c15 line with 4-hydroxytamoxifen (4-OHT)-inducible constructs coding for RhoH (HL-60-RhoH) or GFP (HL-60-GFP) 33 as a control. Induction of RhoH or GFP by 4-OHT was confirmed by western blot or fluorescenceactivated cell sorting (FACS) analysis (Figure 3a ). Using microarrays, gene expression of untreated HL-60-RhoH cells was compared with that of HL-60-RhoH cells in which RhoH had been induced. To exclude genes that were induced by 4-OHT alone, 4-OHT-treated HL-60-GFP cells were also included in the analysis. Among the genes found to be specifically upregulated by RhoH, most had no known functions in eosinophil physiology (Supplementary Table S1 ). To further explore the patterns underlying these data, we performed network and Gene Ontology (GO) analysis using Metacore ( Figure 3b and Supplementary Figure S2 ). The resulting interaction network centred on GATA-2, a transcription factor involved in eosinophil differentiation. Similarly, the GO processes associated with the data included 'eosinophil differentiation' and 'eosinophil fate commitment', and a prominent component of these GO processes was again GATA-2, suggesting that RhoH might influence eosinophil differentiation by altering GATA-2 expression.
A link between RhoH and GATA-2 has not been described previously. To investigate which molecular pathways might be involved in RhoH-induced GATA-2 upregulation, we treated HL-60-RhoH cells with inhibitors for different signalling pathways before induction (Figure 3c ). RhoH induction led to upregulation of GATA-2 at the protein level, confirming the microarray data. P38 inhibition resulted in GATA-2 upregulation, but this was not statistically significant. MEK and PI3K inhibition lead to reduced GATA-2 induction, but RhoH also failed to be upregulated under those conditions, suggesting that the inhibitors act upstream of RhoH in this system and that lack of GATA-2 upregulation is likely a consequence of lack of RhoH induction. Interestingly, of the pharmacological inhibitors tested, only the ROCK inhibitor SB772022B prevented GATA-2 upregulation without affecting RhoH induction (Figure 3c ), indicating that ROCK is a downstream effector of RhoH and mediates RhoH-induced GATA-2 upregulation.
RhoH is upregulated during differentiation of human eosinophils. As the microarray data suggested a role of RhoH in eosinophilopoiesis, we investigated whether RhoH would regulate this process. We found that RhoH expression was low in undifferentiated HL-60c15 cells, but was upregulated during differentiation into eosinophil-like cells (Figure 4a ). To further substantiate these data in a more physiological system, we isolated HPC and immature myeloid cells from human bone marrow. Immature myeloid cells were differentiated into mature neutrophils by addition of G-CSF, or into eosinophils by addition of IL-5, and analyzed by immunoblot (Figure 4b ). RhoH was barely detectable in HPC and was undetectable in immature myeloid cells, differentiating and mature neutrophils. Differentiation into eosinophils, on the other hand, resulted in strong upregulation of RhoH, explaining the relatively high RhoH levels in mature peripheral blood eosinophils.
RhoH
−/− mice have increased eosinophil numbers in peripheral blood and bone marrow. To investigate a potential role of RhoH in eosinophil differentiation in vivo, we analyzed the peripheral blood and bone marrow of RhoH −/− and wild-type (WT) mice, and found that absolute eosinophil counts were clearly increased in the peripheral blood of knockout mice (Figure 5a) . Similarly, eosinophils were more abundant in the bone marrow of RhoH −/− mice (Figure 5b) , suggesting that the elevated number of eosinophils in peripheral blood was due to increased de novo production. Unexpectedly, we also found that eosinophils in the bone marrow of RhoH −/− mice were more mature than the WT as assessed by morphological criteria (Figure 5c ). Mature eosinophils differ in their surface phenotype from their immature counterparts, having upregulated the eotaxin receptor CCR3 and downregulated CD62L. 34 In agreement with the morphological data, we observed increased CCR3 and decreased CD62L expression in the absence of RhoH, confirming a more mature phenotype (Figure 5d ).
RhoH overexpression leads to reduced eosinophil differentiation in mixed bone marrow chimera. To further substantiate the effects of RhoH on eosinophil differentiation in vivo, we reconstituted the hematopoietic compartment of lethally irradiated IL-5 tg mice with a 1 : 1 mixture of hematopoietic stem and progenitor cells (HSPCs) transduced with either a RhoH overexpressing or control lentivirus vector (Supplementary Figure S3a, b) . Four weeks post transfer, Figure S3e and S5) . In our competitive system, the early (4 weeks) skewing of eosinophils and neutrophils, but not monocytes, suggests that RhoH has a strong negative effect on some, but not all lineage-committed progenitors, including eosinophils. The results at 8 weeks are consistent with previous reports showing that RhoH is a broad negative regulator of hematopoietic stem and/or uncommitted progenitor cell engraftment. 27 As a cautionary note, the latter results may be due in part to allelic differences in the CD45 locus, which was reported to give a competitive advantage to CD45.2 HSPCs in long-term engraftment studies (412 weeks). [35] [36] [37] However, the extent of skewing observed in eosinophils compared with B cells and neutrophils 4 weeks after transfer more strongly supports an effect of RhoH overexpression in eosinophil progenitors than a general effect of the CD45 allele on HSPCs. RhoH does not affect IL-5R expression in primary eosinophils. RhoH has been reported to downregulate the alpha chain of the IL-3 receptor (CD123) in a B cell line, 28 diminishing IL-3 signalling. As eosinophil levels are mainly regulated through the closely related IL-5, and we had observed upregulation of RhoH in response to IL-5 in eosinophils (Figure 1) , we determined if RhoH can downregulate the IL-5 receptor in eosinophils. Although surface expression of the IL-5Rα (CD125) and β-chain (CD131) were reduced following RhoH induction in HL-60c15 cells (Figure 7a ), we observed no difference in IL-5R expression on bone marrow or peripheral blood eosinophils between WT and RhoH −/− mice (Figures 7b and c) , similar to the findings with transgenic animals (Figure 2 ). This suggests that elevated eosinophil numbers in the absence of RhoH are not due to an altered IL-5 receptor expression in vivo.
Lack of RhoH results in increased eosinophil differentiation in vitro and reduced GATA-2 expression in bone marrow. To corroborate our findings that RhoH deficiency promotes de novo eosinophil differentiation, we employed a cell culture model to differentiate eosinophils from mouse bone marrow. 38 Using this model, we observed that eosinophil differentiation is indeed enhanced in the absence of RhoH (Figure 8 ). Importantly, although the percentage of eosinophils was higher in the bone marrow of RhoH −/− mice at the beginning of the culture, at day 6 virtually no eosinophils could be detected in either knockout or WT cultures, excluding the possibility that the differences observed were due to eosinophils surviving through the culture period. Newly differentiating eosinophils were discernible from day 8 onwards and subsequently developed into mature cells. This process was accelerated in the absence of RhoH as shown by increased eosinophil numbers (Figures 8a and b) and faster maturation as assessed by morphology and CCR3/CD62L expression (Figures 8c  and d) . Again, no differences in IL-5R expression were detectable ( Supplementary Figures S6a and b) .
To address a possible role of GATA-2 in the observed phenotype, we assessed the expression of GATA-2, as well as that of GATA-1 and PU.1 in the bone marrow of WT and RhoH −/− mice. While GATA-1 and PU.1 levels were unchanged, GATA-2 mRNA and protein expression were reduced in the absence of RhoH (Figures 8e and f) , suggesting that RhoH also regulates GATA-2 levels in vivo.
Lack of RhoH is associated with increased numbers of differentiating eosinophils entering the cell cycle. An increased number of eosinophils in the absence of RhoH could be the result of decreased cell death during differentiation or increased proliferation. As induction of GATA-2 has been reported to affect cell cycling and proliferation of HPC by increasing their quiescence (G0) residency, 10 we examined cell cycle phase distribution and viability of freshly isolated bone marrow cells and during eosinophil differentiation in vitro. While we did not observe any differences in viability (Supplementary Figure S6c) , we found that RhoH deficiency did have an effect on the cell cycle ( Figure 9 ). Using a staining protocol with 7-AAD and pyronin Y, which allows the discrimination of cells in G1 from cells in G0, as well as S and G2/M phases, we found that in the absence of RhoH, the percentage of quiescent cells having withdrawn from the cell cycle (G0) was reduced, while the percentage of cells in G1 was increased (Figure 9a ). These alterations were analogous to those that have been reported for cells with increased GATA-2 levels. 10 We also observed a small, nonsignificant increase in cells in S phase, but no effect on G2/M was apparent. As quiescent cells in G0 do not proliferate, the shift from G0 to G1 and possibly S indicates increased proliferation of progenitors as the mechanism underlying enhanced eosinophil generation when RhoH is lacking. On the other hand, when RhoH is present, a larger fraction of cells was quiescent (i.e., in G0). In order to see whether this phenomenon was detectable only at the onset of eosinophil differentiation or during the entire process, we performed the analysis each second day of the differentiation protocol (Figure 9b ). The shift from G0 to G1 (and possibly S) in the absence of RhoH was largely maintained during eosinophil differentiation until day 10 ( Figure 9b ). These results suggest that RhoH limits eosinophil differentiation through its effect on the cell cycle, that is, by increasing quiescence (G0 residency). As RhoH induces GATA-2 (Figures 3 and 7) and GATA-2 induction has been reported to have the same effect, 10 our results are consistent with RhoH limiting eosinophil differentiation by this mechanism.
Discussion
Our results identify RhoH as a novel negative regulator of eosinophil differentiation. Reduced eosinophil numbers in the presence of RhoH appear to be due to limited differentiation of eosinophils in the bone marrow rather than enhanced death of eosinophils as has recently been reported for the negative regulator PIR-A. 39 Furthermore, RhoH could induce GATA-2, whereas GATA-2 expression was reduced in vivo in the absence of RhoH. RhoH limited eosinophil differentiation and maturation both in vitro and in vivo, likely by regulating GATA-2 levels and the cell cycle.
RhoH appears to have different functions in different hematopoietic cells. Although our data show that eosinophil differentiation is enhanced in the absence of RhoH, T-cell development is impaired and mast cell development unaffected. 21, 26 Neutrophil numbers are also unchanged, probably due to the fact that they express little or no RhoH. This observed enhancement results in increased peripheral eosinophil numbers, but the function of mature eosinophils released into the periphery is apparently not impacted, as indicated by the results using eosinophils from IL-5 tg and RhoH −/− IL-5 tg mice. Similarly, surface expression of the maturation markers CD62L and CCR3 on mature peripheral blood eosinophils from these mice (Figure 2) or from WT and RhoH −/− mice did not differ between genotypes (not shown). The observation that differences in maturation markers are restricted to the bone marrow supports the idea that increased peripheral blood eosinophil numbers in the absence of RhoH are the consequence of increased eosinophil production in the bone marrow rather than enhanced release of immature eosinophils in these mice.
HPC proliferation, survival, engraftment and migration have been reported to be increased by knocking down RhoH, 27 and our results using bone marrow chimeras of RhoH overexpressing and control transduced progenitors/stem cells confirm these results. Interestingly, mature eosinophil survival or migration was unaffected in our study. However, our results support the idea that RhoH can negatively regulate proliferation of eosinophils during differentiation, by reducing GATA-2 levels and inducing a shift from G1 to the G0 phase of cell cycle.
Reports on the role of GATA-2 in eosinophil differentiation and function have shown that it can have positive, as well as negative regulatory functions. [8] [9] [10] [11] [12] [13] [14] As GATA-2 cooperates and competes with a number of transcription factors, these apparently contrasting results are likely due to differences in experimental systems and corresponding differences in the relative levels of GATA-2 and its interaction partners or competitors. Our results indicate that a partial reduction in physiological GATA-2 levels as a result of RhoH deficiency promotes differentiation into the eosinophil lineage. Importantly, GATA-1 levels were unaffected in RhoH −/− mice, suggesting that a shift in the GATA-1/GATA-2 balance could alleviate GATA-2 antagonism of GATA-1-mediated gene expression during eosinophil development.
Interestingly, we found that ROCK activity was required for RhoH-induced GATA-2 upregulation. ROCK is a downstream effector of several Rho proteins and has critical roles in cell cycle progression, cell survival and proliferation. 40 Although RhoH has so far not been described to affect ROCK activity, it has been reported to antagonize Rac, and Rac can block Rho/ROCK signalling. 27, 40 Whether RhoH affects ROCK directly, or indirectly, for example, through relieving Racmediated antagonism of ROCK, remains to be investigated. Although ROCK has been shown to be important for cell cycle progression, it appears to affect the G1 to S transition rather than, like GATA-2, the G0 to G1 transition. 41 Our results are, therefore, more compatible with the notion that ROCK-induced GATA-2 expression, rather than ROCK activity per se, is involved in the observed phenotype.
Besides its role in eosinophil differentiation, RhoH likely also has a role in mature eosinophils, as it is strongly and rapidly upregulated upon cytokine exposure in vitro and highly expressed in some HES patients, probably as a consequence of in vivo cytokine exposure. This rapid increase in RhoH protein might be facilitated by the comparatively high levels of mRNA stored in eosinophils (Figure 1a ). In neutrophils, RhoH has been reported to limit cytokine-induced LTB4 production. 29 Although this suggests that in mature eosinophils, RhoH could also act as a negative feedback regulator of cytokine signalling, we found no evidence for differences in IL-5-mediated survival or eotaxin-induced migration between mouse eosinophils with or without RhoH expression.
As eosinophils play major roles in asthma and allergy, eosinophil-directed therapies are currently being tested. 18 While many of these successfully reduce peripheral blood eosinophil counts, they fail to eradicate tissue eosinophils. Therefore, treatments targeting de novo generation in the bone marrow and, therefore, long-term depletion might be promising. However, development of such treatments is clearly hampered by a lack of understanding of eosinophilopoiesis. For most of the genes found to be upregulated in the microarray analysis, a role in granulopoiesis/eosinophilopoiesis has not been investigated so far. As very few factors governing eosinophil generation and maturation are known (and even fewer negative regulators), and as RhoH negatively regulates eosinophil differentiation, our data warrant further studies to elucidate the exact molecular mechanisms underlying these processes.
The notion that RhoH influences transcription factors governing leukocyte differentiation is also highly interesting in a slightly different context. RhoH is frequently mutated in lymphomas and leukemias and mutations often correlate with prognosis, either poor or favorable, depending on the specific malignancy, precluding a role for RhoH as classical tumor suppressor or oncogene. 19 The molecular basis for these apparently contradictory observations is unclear. However, shifts in the balance of transcription factors related to hematopoietic differentiation have been implicated in the pathogenesis of leukemia and therapeutic agents affecting that balance are used successfully in the clinic (e.g., all-trans retinoic acid for acute myeloid leukemia). 42 A clearer view of how this network is regulated might also open up new possibilities for interventions to treat hematopoietic malignancies.
Materials and Methods
Antibodies and flow cytometry. Details are provided in the Supplementary Information.
Leukocyte isolation and culture from human blood and bone marrow. Leukocyte subsets were isolated from Li-heparinized blood as outlined in the Supplementary Information. For some experiments, eosinophils were cultured in RPMI 5% FCS with or without 10 ng/ml IL-5, IL-3 (R&D Systems, Minneapolis, MN, USA), or GM-CSF (Novartis, Basel, Switzerland, Leukomax 300).
HPC and immature myeloid precursors were isolated from human bone marrow as previously described. 43 Precursors were differentiated with 25 ng/ml G-CSF (neutrophils) or 10 ng/ml IL-5 (eosinophils). For details, see Supplementary Information.
Generation and culture of stably transduced HL-60 clone 15 cells. For generation of cell lines inducibly overexpressing RhoH see Supplementary Information. For inhibitor experiments, cells were pre-treated with SB772077B dihydrochloride (1 μM, Tocris Bioscience, Bristol, UK), PD169316, LY294002 (both 10 μM, Calbiochem, Darmstadt, Germany), PD98059 (50 μM, Calbiochem) or FIPI hydrochloride (1 μM, R&D Systems) 45 min before induction with 100 nM 4-OHT.
RT-qPCR, microarray and bioinformatics analysis. pPCR or microarray analysis using the Affimetrix Human Gene 2.0 ST Array (Affimetrix, Santa Clara, CA, USA) were performed as outlined in the Supplementary Information.
Mice and isolation of mouse eosinophils. Animal studies were approved by the Veterinary Office of the Canton of Bern and conducted in accordance with Swiss federal legislation on animal welfare. RhoH −/− mice 24 were provided by Cord Brakebusch (University of Copenhagen, Denmark) and WT C57/B6 mice by the in-house facility. For functional tests, eosinophils were isolated from IL-5 tg (C57BL/6J-Tg(Il5)1638Jlee), 16 provided by Jamie Lee (Mayo Clinic, Scottsdale, Arizona), and RhoH −/− IL-5 tg mice, which were generated by crossing IL-5 tg mice to RhoH −/− mice. For eosinophil isolation, spleens were mechanically dissociated and RBC lysed with ACK buffer. T cells, B cells and macrophages were depleted with antibodies against CD8α, CD90.2 and CD19 (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain eosinophils (490% pure by Diff-Quik).
Differentiation of eosinophils from bone marrow of 12-24-week-old mice was performed as described. 38 Briefly, bone marrow of age-and sex-matched mice was cultured in the presence of Flt3L and SCF (Peprotech) for 4 days, and subsequently with IL-5 (R&D systems) for 10 days with medium replacement every 2 days. 
